Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial
Pediatrics · 01.06.2026 · 157 (6)
DOI: 10.1542/peds.2025-075223 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pediatrics, online erschienen am 04.05.2026. Verfasst von Christina A Rostad und 30 weiteren Autor:innen. Beteiligte Einrichtung: Children's Healthcare of Atlanta Arthur M. Blank Hospital, Emory University School of Medicine, Atlanta, Georgia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
BACKGROUND Although both maternal respiratory syncytial virus (RSV) prefusion F vaccination (RSVpreF) and infant nirsevimab immunization have been approved for the prevention of RSV lower respiratory tract infections, the 2 have not been evaluated in a single study, and their sequential administration has not been studied systematically. METHODS We performed a prospective, randomized, open-label, phase 4 study at 8 US sites of mother-infant pairs randomized 1:1:1:1 during pregnancy: maternal RSVpreF vaccine alone, maternal RSVpreF vaccine/infant nirsevimab at birth, maternal RSVpreF vaccine/infant nirsevimab at 3 months, or infant nirsevimab alone at birth. We are following the mother-infant pairs for 12 months to ascertain safety, infant tolerability, and the magnitude and durability of RSV-A and -B neutralizing antibodies (nAbs). We report interim data from September 19, 2024, to May 15, 2025, including 4-month infant follow-up. RESULTS In total, 181 mothers were enrolled. Both products alone and in combination were safe. No related serious adverse events were observed in mothers or infants. Nirsevimab was well tolerated, and all local and systemic reactogenicity was mild to moderate in severity. RSVpreF vaccination boosted maternal RSV-A nAb titers 17.35-fold at the time of delivery, and titers were durable through 3 months postdelivery. The geometric mean transfer ratio of RSV-A nAbs was higher than 1.3 and similar across groups. RSV nAbs were highly elevated in infants at 6 weeks and 3 months, irrespective of group, with modest differences in waning. CONCLUSIONS Maternal RSVpreF vaccine and infant nirsevimab administration, either alone or in combination, were safe and provided high RSV nAb titers in infants through interim follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Children's Healthcare of Atlanta Arthur M. Blank Hospital, Emory University School of Medicine, Atlanta, Georgia.
- Baylor College of Medicine, Houston, Texas.
- UR Medicine, University of Rochester, Rochester, New York.
- NYU Grossman School of Medicine, New York University, New York, New York.
- Vanderbilt University Medical Center, Nashville, Tennessee.
- University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Förderung
- NIAID NIH HHS
Zitieren
APA
Rostad, C. A., Healy, C. M., Nayak, J. L., Parameswaran, L., Creech, C. B., Martin, J. M., Brady, R. C., Jones-Beatty, K., Badell, M., Eppes, C., Quinn, M., Mulligan, M., Rolsma, S. L., Rick, A. M., Forde, B., Avadhanula, V., Piedra, P. A., Telu, K., Kunwar, P. S., …, & DMID 24-0003 PROMISE Study Group (2026). Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial. Pediatrics, 157(6). https://doi.org/10.1542/peds.2025-075223
Vancouver
Rostad CA, Healy CM, Nayak JL, Parameswaran L, Creech CB, Martin JM, et al. Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial. Pediatrics. 2026;157(6). doi:10.1542/peds.2025-075223
BibTeX
@article{Rostad2026,
author = {Rostad, Christina A and Healy, C Mary and Nayak, Jennifer L and Parameswaran, Lalitha and Creech, C Buddy and Martin, Judith M and Brady, Rebecca C and Jones-Beatty, Kimberly and Badell, Martina and Eppes, Catherine and Quinn, Michael and Mulligan, Mark and Rolsma, Stephanie L and Rick, Anne-Marie and Forde, Braxton and Avadhanula, Vasanthi and Piedra, Pedro A and Telu, Kalyani and Kunwar, Pratap S and Mu, Jinjian and Gao, Fei and Pasetti, Marcela F and Flach, Britta and Posavad, Christine M and Miedema, Joy and Piper, Jeanna M and Kim, Sonnie and Beresnev, Tatiana and Cardemil, Cristina and Campbell, James D and DMID 24-0003 PROMISE Study Group, DMID 24-0003 PROMISE Study Group},
title = {Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial},
journal = {Pediatrics},
year = {2026},
volume = {157},
number = {6},
doi = {10.1542/peds.2025-075223}
}
EUVIMED